Major Depressive Disorder, often called MDD, remains one of the most disabling mental health conditions worldwide. For individuals who do not respond to antidepressant medications, treatment resistant depression can feel overwhelming and discouraging. In recent years, repetitive transcranial magnetic stimulation, known as rTMS, has emerged as a promising noninvasive treatment option.
A 2026 research paper published in the Journal of Affective Disorders examined whether an accelerated rTMS protocol could work as well as the traditional once daily approach. This blog post provides an SEO optimized summary of that study, its clinical implications, and what it may mean for people exploring rTMS for depression.
Repetitive transcranial magnetic stimulation is an FDA cleared neuromodulation therapy for depression. It uses magnetic pulses delivered to the left dorsolateral prefrontal cortex, a brain region involved in mood regulation.
Unlike medications, rTMS does not require systemic drug exposure. It is typically administered in an outpatient setting and does not require anesthesia. Standard treatment involves one session per day, five days per week, for about six weeks.
Research has shown that rTMS can be effective even after multiple antidepressant medications have failed. However, the time commitment of six weeks can be a barrier for some patients. This has led researchers to explore accelerated rTMS protocols designed to deliver multiple sessions per day over a shorter period.
The 2026 study titled “Efficacy of 5 × 5 accelerated versus conventional repetitive transcranial magnetic stimulation for treatment resistant depression” evaluated whether a five sessions per day for five days model, referred to as the 5 × 5 protocol, was as effective as the traditional once daily approach.
The research was conducted at the UCLA TMS Clinical and Research Service in Los Angeles between February 2023 and March 2025. The study included 175 patients diagnosed with Major Depressive Disorder.
The accelerated protocol delivered five stimulation sessions per day for five consecutive days. The conventional protocol delivered one session per day, five days per week, for six weeks.
The primary outcome measure was the PHQ 9, a widely used depression severity scale.
Both the accelerated and conventional rTMS protocols significantly improved depression symptoms.
Although the conventional group showed slightly greater symptom reduction at treatment completion, the difference between groups was not statistically significant.
The statistical comparison between the accelerated 5 × 5 protocol and the standard once daily protocol showed no significant difference in depression symptom improvement.
This suggests that delivering five sessions per day for five days may be comparable in effectiveness to spreading sessions out over six weeks.
One of the most interesting findings involved patients who did not initially respond to the accelerated treatment.
When researchers split the accelerated group into two halves based on response:
However, at a two to four week follow up, the initially nonresponsive group showed significant improvement, with a 36 percent improvement rate.
This highlights an important clinical insight. The full effect of accelerated rTMS may not be visible immediately at the end of the five day treatment period.
Treatment resistant depression is common. Many patients do not achieve remission with their first antidepressant. Traditional medication management can involve months or even years of trial and error.
Accelerated rTMS protocols may offer several potential advantages:
For individuals who need rapid improvement due to severe functional impairment or personal constraints, a five day intensive protocol may be appealing.
However, the delayed improvement seen in some patients underscores the importance of follow up assessment. Clinicians should not assume that lack of immediate improvement means treatment failure.
Accelerated rTMS approaches have gained attention in recent years. Some FDA cleared accelerated protocols involve up to 10 sessions per day over five days.
Interestingly, previous research has suggested that more intensive stimulation does not always produce better outcomes. Some studies of deep TMS have found lower response rates with extremely high intensity daily schedules compared to moderately accelerated schedules.
The 5 × 5 approach may represent a balanced middle ground. It provides rapid delivery of treatment without pushing the intensity to extremes.
Further randomized controlled trials will be necessary to determine optimal session number, pulse count, and stimulation parameters.
For many patients, accelerated 5 × 5 rTMS may offer symptom improvement comparable to standard six week treatment. The primary difference lies in the timeline rather than overall effectiveness.
The study emphasizes that treatment outcomes should not be judged only at the final session. Some patients may experience continued neurobiological changes in the weeks after stimulation ends.
This delayed response pattern suggests clinicians should schedule structured follow up visits two to four weeks after accelerated treatment completion.
Not all patients respond the same way. Factors such as severity, duration of illness, comorbid conditions, and neurophysiological characteristics may influence who benefits most from accelerated protocols.
Shared decision making between patient and clinician remains essential.
While the results are promising, several limitations should be considered:
Because of these limitations, the findings should be interpreted as preliminary rather than definitive.
Randomized controlled trials are needed to confirm whether 5 × 5 accelerated rTMS is truly equivalent to conventional protocols.
The field of neuromodulation continues to evolve rapidly. Researchers are investigating:
The goal is to refine protocols so that treatment resistant depression can be addressed more quickly, effectively, and sustainably.
As the evidence base grows, clinicians may be able to better match patients to the most appropriate stimulation schedule.
Accelerated rTMS uses the same technology as standard protocols. The primary difference is session frequency. Safety monitoring remains essential, but current evidence suggests comparable safety profiles.
Each session feels similar to standard rTMS. The main difference is spending more time in the clinic each day for a shorter overall duration.
Coverage varies by provider and region. Many insurers cover standard rTMS. Accelerated protocols may require additional documentation or prior authorization.
The 2026 study published in the Journal of Affective Disorders suggests that a 5 × 5 accelerated rTMS protocol may be as effective as conventional once daily rTMS for many patients with treatment resistant depression.
While immediate response rates may vary, significant symptom improvement can occur in the weeks following treatment. These findings highlight the importance of follow up assessment and open the door to more flexible treatment scheduling options.
For patients struggling with persistent depression despite medication trials, accelerated rTMS may represent a meaningful and time efficient alternative. However, further randomized clinical trials are needed before definitive conclusions can be drawn.
Apostol MR, Valles TE, Corlier J, et al. Efficacy of 5 × 5 accelerated versus conventional repetitive transcranial magnetic stimulation for treatment resistant depression. Journal of Affective Disorders. Volume 403. 15 June 2026. Article 121345.
This blog post is for informational and educational purposes only and is not intended as medical advice. It does not replace consultation with a qualified healthcare professional. If you or someone you know is experiencing depression or worsening symptoms, seek evaluation from a licensed mental health provider. Treatment decisions should always be made in collaboration with a qualified clinician based on individual circumstances.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.